In the literature, ERCC1 rs3212986 is also described in association with treatment response, cancer risk, and overall survival [78,79,80,81] and with poor response to chemotherapy and shorter survival time of advanced NSCLC [82]. This evidence concerns the gene ERCC1 and cancer.